Jana Sanders, PA
Physician Assistant · Sebring, FLNPI 1568530160
Payments from drug & device makers
Across 182 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$798
- Takeda Pharmaceuticals U.S.A., Inc.$590
- GSK$421
- Otsuka America Pharmaceutical, Inc.$294
- Insmed, Inc.$247
- Regeneron Healthcare Solutions, Inc.$171
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,10897%
- Education$1213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $798 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $590 |
| GSK | 25 | $421 |
| Otsuka America Pharmaceutical, Inc. | 13 | $294 |
| Insmed, Inc. | 8 | $247 |
| Regeneron Healthcare Solutions, Inc. | 4 | $171 |
| AbbVie | 7 | $156 |
| Teva Pharmaceuticals USA, Inc. | 6 | $149 |
| United Therapeutics Corporation | 6 | $141 |
| Amgen | 6 | $126 |
| Mylan Specialty L.p. | 7 | $121 |
| Alkermes, Inc. | 5 | $105 |
| Boehringer Ingelheim | 5 | $104 |
| Axsome Therapeutics, Inc. | 4 | $96 |
| Sanofi | 3 | $92 |
| Viatris Specialty LLC | 3 | $91 |
| Grifols USA, LLC | 4 | $77 |
| Neurocrine Biosciences, Inc. | 4 | $76 |
| Inspire Medical Systems, Inc. | 1 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Corcept Therapeutics | 2 | $35 |
| Almatica Pharma LLC | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Baxter Healthcare | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Harmony Biosciences LLC | 1 | $19 |
| Inogen, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$125
How this compares
$4,229 in reported general payments places this provider in the 85th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 293 | $312,085 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 186 | $224,288 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $124,025 |
| FasenraBenralizumab | 16 | $92,203 |
| MounjaroTirzepatide | 74 | $83,600 |
| NucalaMepolizumab | 12 | $40,902 |
| EliquisApixaban | 38 | $40,724 |
| OzempicSemaglutide | 21 | $28,960 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $19,091 |
| Spiriva HandihalerTiotropium Bromide | 18 | $18,161 |
| TrulicityDulaglutide | 16 | $14,941 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $14,684 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $10,881 |
| MyrbetriqMirabegron | 15 | $9,577 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $9,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $421 | $363,868319 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort | $798 | $335,582248 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $590 | $124,02512 claims |
| Lilly USA, LLCMounjaro, Trulicity | $20 | $98,54190 claims |
| Novo NordiskOzempic | $16 | $28,96021 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $104 | $24,07631 claims |
| AbbVieSynthroid | $156 | $1,61118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Sebring
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.